Stock comparison
IDEXX Laboratories
Telix Pharmaceuticals Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
TLX
Telix Pharmaceuticals Limited
Market cap
$3.21B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | TLX | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 31F | IDXX |
| Benjamin Graham | 80A | 49D | IDXX |
| Philip Fisher | 75B | 50C | IDXX |
| Peter Lynch | 71B | 29F | IDXX |
| Joel Greenblatt | 83C | 0F | IDXX |
| Charlie Munger | 87A | 44D | IDXX |
| Terry Smith | 84A | 38D | IDXX |
Side-by-side metrics
| Metric | IDXX | TLX |
|---|---|---|
| Market cap | $44.12B | $3.21B |
| P/E (TTM) | 39.0x | - |
| EV/EBIT | 31.6x | 211.6x |
| ROIC (TTM) | 40.66% | 1.77% |
| Gross margin | 62.05% | 50.76% |
| Net margin | 24.63% | -0.89% |
| Revenue CAGR 5y | 7.56% | 2.55% |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | 1.3x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Net margin24.63%vs -0.89%+104%
- ROIC (TTM)40.66%vs 1.77%+96%
- Market cap$44.12Bvs $3.21B+93%
- EV/EBIT31.6xvs 211.6x+85%
TLX leads on
- P/E (TTM)-vs 39.0x+108%
- Revenue CAGR 5y2.55%vs 7.56%+97%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.